Latest News on ADPT

Financial News Based On Company


Advertisement
Advertisement

Cathie Wood’s ARK buys Anthropic stock, sells Nvidia and Adaptive Bio

https://www.investing.com/news/company-news/cathie-woods-ark-buys-anthropic-stock-sells-nvidia-and-adaptive-bio-93CH-5040446
Cathie Wood's ARK ETFs made significant portfolio adjustments on November 19, 2026, purchasing nearly 1 million shares of AI company Anthropic, PBC for over $77 million. Concurrently, ARK divested from several companies, including Adaptive Biotechnologies and NVIDIA, continuing a trend of reducing its semiconductor holdings. The firm also sold stakes in cryptocurrency-related ETFs and made smaller trades in Garmin, Heico, and Eli Lilly, while increasing its positions in Kodiak AI, Twist Bioscience, and GeneDx Holdings.

Adaptive Biotechnologies clonoSEQ to feature in ~100 ASH abstracts

https://www.streetinsider.com/Corporate+News/Adaptive+Biotechnologies+clonoSEQ+to+feature+in+~100+ASH+abstracts/27366059.html
Adaptive Biotechnologies announced that its clonoSEQ test for measurable residual disease (MRD) assessment will be featured in approximately 100 abstracts, including 27 oral presentations, at the 68th Annual Meeting of the American Society of Hematology (ASH). The presentations will cover 20 biopharma-sponsored studies, with clonoSEQ serving as a primary or secondary endpoint in multiple Phase 3 trials for various hematologic cancers like multiple myeloma and chronic lymphocytic leukemia. The clonoSEQ test is FDA-cleared for MRD detection in several conditions and is also available as a CLIA-validated laboratory-developed test.

A cancer test can detect 1 cell in 1 million healthy cells. New research will examine its role in treatment decisions.

https://www.stocktitan.net/news/ADPT/adaptive-biotechnologies-highlights-clono-seq-s-central-role-in-98d1tr8wks4n.html
Adaptive Biotechnologies announced that its clonoSEQ test, which detects measurable residual disease (MRD) in cancer patients, will be featured in approximately 100 abstracts at the American Society of Hematology annual meeting. The research highlights clonoSEQ's expanding role in informing treatment decisions across multiple myeloma, chronic lymphocytic leukemia, and diffuse large B-cell lymphoma. The company emphasizes the test's ability to assess long-term treatment response, guide therapy strategies, and potentially identify patients with sustained MRD negativity and survival comparable to the general population.

Form 144 Adaptive Biotechnologies Corp For: 15 November By Investing.com

https://ca.investing.com/news/stock-market-news/form-144-adaptive-biotechnologies-corp-for-15-november-93CH-4959066
This article announces the filing of Form 144 by Adaptive Biotechnologies Corp for November 15. Form 144 is a notice of the intent to sell restricted securities. The brief notice from Investing.com indicates this filing without providing further details on the transaction.

Form 144 Adaptive Biotechnologies Corp For: 15 November By Investing.com

https://in.investing.com/news/stock-market-news/form-144-adaptive-biotechnologies-corp-for-15-november-93CH-5705163
Investing.com published a Form 144 filing for Adaptive Biotechnologies Corp, dated November 15, 2026. This report is a standard disclosure document related to the proposed sale of restricted securities. The article provides minimal details beyond the filing's existence and date.
Advertisement

Form 144 Adaptive Biotechnologies Corporation For: 14 November By Investing.com

https://ca.investing.com/news/stock-market-news/form-144-adaptive-biotechnologies-corporation-for-14-november-93CH-4958838
This article announces the filing of Form 144 for Adaptive Biotechnologies Corporation (ADPT) for November 14. Form 144 is a notice of the intent to sell restricted stock. The article provides the title and the company's stock symbol along with its recent price change.

Adaptive Biotechnologies (NASDAQ:ADPT) COO Julie Rubinstein Sells 11,466 Shares of Stock

https://www.marketbeat.com/instant-alerts/insider-adaptive-biotechnologies-nasdaq-adpt-coo-julie-rubinstein-sells-11466-shares-of-stock-2026-11-13/
Adaptive Biotechnologies COO Julie Rubinstein sold 11,466 shares of ADPT stock on Friday, November 13th, for a total of $331,711.38, reducing her position by 2.95%. This sale was part of a pre-arranged Rule 10b5-1 trading plan, and she has made several similar sales in recent weeks. The company recently reported better-than-expected quarterly earnings of $0.02 EPS and $83.9 million in revenue, leading analysts to a "Moderate Buy" consensus rating with an average price target of $30.31.

An officer sold at $32 a share under a trading plan at Adaptive Biotechnologies (ADPT).

https://www.stocktitan.net/sec-filings/ADPT/form-4-adaptive-biotechnologies-corp-insider-trading-activity-21b9d1612e34.html
Susan Bobulsky, Chief Commercial Officer for MRD at Adaptive Biotechnologies Corp (ADPT), sold 1,875 shares of common stock on November 11, 2026, at $32 per share. This transaction was conducted under a Rule 10b5-1 trading plan adopted on December 16, 2025, leaving her with 387,475 direct holdings after the sale. The filing highlights key figures of the sale and explains the regulatory context of a Rule 10b5-1 trading plan.

Adaptive Biotechnologies (ADPT) COO sells shares under a preset trading plan.

https://www.stocktitan.net/sec-filings/ADPT/form-4-adaptive-biotechnologies-corp-insider-trading-activity-cdba0d5c7a59.html
Adaptive Biotechnologies Corp. (ADPT) President and COO Julie Rubinstein exercised options and subsequently sold a total of 35,228 shares of common stock between November 11 and November 13, 2026. These transactions, generating approximately $620K in pre-tax spread, were conducted under a Rule 10b5-1 trading plan established on November 18, 2025.

Form 4 Adaptive Biotechnologies Corp: Chad M. Robins (Director, CEO and Chairman) For: 9 November

https://in.investing.com/news/stock-market-news/form-4-adaptive-biotechnologies-corp-chad-m-robins-director-ceo-and-chairman-for-9-november-93CH-5701512
This article reports on a Form 4 filing for Adaptive Biotechnologies Corp (ADPT), detailing a transaction involving Chad M. Robins, who holds positions as Director, CEO, and Chairman. The filing pertains to activity on November 9th. The article mentions a minor stock price change for ADPT.
Advertisement

Form 4 Adaptive Biotechnologies Corp: Chad M. Robins (Director, CEO and Chairman) For: 9 November

https://uk.investing.com/news/stock-market-news/form-4-adaptive-biotechnologies-corp-chad-m-robins-director-ceo-and-chairman-for-9-november-93CH-4979411
This article reports on a Form 4 filing for Adaptive Biotechnologies Corp, detailing an insider transaction involving Chad M. Robins, who serves as a Director, CEO, and Chairman. The transaction date specified in the filing is November 9. The report was published by Investing.com.

After gifting 100,000 shares, Adaptive Biotechnologies (ADPT) CEO holds 2,080,518 shares directly.

https://www.stocktitan.net/sec-filings/ADPT/form-4-adaptive-biotechnologies-corp-insider-trading-activity-170d1e431cd7.html
Adaptive Biotechnologies Corp (ADPT) CEO and Chairman Chad M. Robins reported a bona fide gift disposition of 100,000 common shares on November 9, 2026, to the Robins Nest Family Foundation. Following this transaction, Mr. Robins directly holds 2,080,518 common shares. The filing indicates a neutral sentiment and impact.

A family foundation proposes selling 73,221 Adaptive Biotechnologies (ADPT) shares.

https://www.stocktitan.net/sec-filings/ADPT/144-adaptive-biotechnologies-corp-sec-filing-88c425a992ef.html
The Robins Nest Family Foundation, through Chad Robins, has proposed selling 73,221 common shares of Adaptive Biotechnologies (ADPT) with an aggregate market value of $2,192,236.74. Goldman Sachs & Co. LLC is listed as the broker for this transaction, which has an approximate sale date of November 11, 2026. The filing was accepted by the SEC on November 12, 2026.

Adaptive Biotechnologies (ADPT) Lands In $17.1 Billion DNA Sequencing Market Report

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adpt/adaptive-biotechnologies/news/adaptive-biotechnologies-adpt-lands-in-171-billion-dna-seque
Adaptive Biotechnologies (ADPT) has been recognized as a leading innovator in a new report projecting the global DNA sequencing market to reach $17.1 billion by 2030, driven by expanded clinical adoption and use cases in precision medicine and oncology. This spotlight reinforces the company's "clonoSEQ" product's role in clinical practice and trials, even as the company reported softer Q3 2026 sales and a net loss for the year to date. The report also highlights pressure on the company's Immune Medicine unit to secure high-margin pharma partnerships to balance sequencing attention with financial performance.

An officer sells 1,875 Adaptive Biotechnologies (ADPT) shares under a trading plan.

https://www.stocktitan.net/sec-filings/ADPT/144-adaptive-biotechnologies-corp-sec-filing-3b1e8801e51f.html
Adaptive Biotechnologies Corporation officer Susan Bobulsky sold 1,875 common shares on November 11, 2026, for an aggregate market value of $55,050. These shares were acquired as restricted stock units on March 4, 2024, and the sale was conducted under a Rule 10b5-1 plan adopted on December 16, 2025. This Form 144 filing also references two earlier sales by Bobulsky in October and September 2026.
Advertisement

Adaptive Biotechnologies (NASDAQ:ADPT) COO Julie Rubinstein Sells 11,881 Shares of Stock

https://www.marketbeat.com/instant-alerts/insider-adaptive-biotechnologies-nasdaq-adpt-coo-julie-rubinstein-sells-11881-shares-of-stock-2026-11-10/
Adaptive Biotechnologies COO Julie Rubinstein sold 11,881 shares of the company's stock on November 9th for a total of $357,855.72, bringing her remaining ownership to 377,802 shares. This transaction was part of a pre-arranged Rule 10b5-1 trading plan, and follows multiple similar sales throughout October and November. The company recently reported quarterly earnings that exceeded analyst expectations, with EPS of $0.02 and revenue of $83.9 million, despite a 10.7% year-over-year revenue decrease.

Adaptive Biotechnologies COO Julie Rubinstein sells $708,557 in stock

https://www.investing.com/news/insider-trading-news/adaptive-biotechnologies-coo-julie-rubinstein-sells-708557-in-stock-93CH-5017442
Adaptive Biotechnologies COO Julie Rubinstein sold 23,762 shares of the company's common stock for $708,557 in November 2026, executed under a Rule 10b5-1 trading plan. These sales occurred after she acquired an equivalent number of shares by exercising stock options at a lower price. The transactions took place as the stock traded near its 52-week high, following a 102% return over the past year, with InvestingPro analysis suggesting the stock is overvalued.

COO exercises 11,881 options on each of two days and sells shares at Adaptive Biotechnologies (ADPT).

https://www.stocktitan.net/sec-filings/ADPT/form-4-adaptive-biotechnologies-corp-insider-trading-activity-515163c4e931.html
Adaptive Biotechnologies President and COO Julie Rubinstein exercised 11,881 options at $12.14 per share on both November 9 and November 10, 2026, acquiring common shares. She then sold a total of 23,762 shares over these two days at weighted average prices ranging from $28.87 to $30.58. These transactions were executed under a Rule 10b5-1 trading plan adopted in November 2025.

Biotech conference talks are planned in London and New York

https://www.stocktitan.net/news/ADPT/adaptive-biotechnologies-to-participate-in-upcoming-investor-14kowd4qrnd0.html
Adaptive Biotechnologies (ADPT) announced its participation in two upcoming investor conferences: the Jefferies Global Healthcare Conference in London on November 18, 2026, and the Piper Sandler 38th Annual Healthcare Conference in New York on December 2, 2026. The company will deliver a presentation and a fireside chat, respectively, with webcasts available through its investor relations website. This news aims to keep investors informed about the company's engagements and provides details on accessing the conference content.

Adaptive Biotechnologies to Participate in Upcoming Investor Conferences

https://www.globenewswire.com/news-release/2026/11/10/3400222/0/en/adaptive-biotechnologies-to-participate-in-upcoming-investor-conferences.html
Adaptive Biotechnologies (Nasdaq: ADPT) announced its participation in two upcoming investor conferences: the Jefferies Global Healthcare Conference on November 18, 2026, and the Piper Sandler 38th Annual Healthcare Conference on December 2, 2026. The company, which focuses on leveraging the adaptive immune system for disease diagnosis and treatment, will provide live and archived webcasts of its sessions on its investor relations website. This engagement offers investors insights into Adaptive Biotechnologies' progress and future plans.
Advertisement

Julie Rubinstein Executes Option Exercises and Sells Adaptive Biotechnologies Shares on Nov 9-10, 2026

https://kalkinemedia.com/us/news/announcements/julie-rubinstein-executes-option-exercises-and-sells-adaptive-biotechnologies-shares-on-nov-9-10-2026
Julie Rubinstein, President and COO of Adaptive Biotechnologies Corp (NASDAQ:ADPT), conducted option exercises and subsequent sales of common stock on November 9 and 10, 2026. These transactions, executed under a pre-established Rule 10b5-1 trading plan, involved exercising 11,881 shares on each day at $12.14 per share, followed by multiple tranches of sales at various weighted average prices. After these activities, Rubinstein's direct beneficial ownership in the company stands at 377,802 shares.

Adaptive Biotechnologies stock hits 52-week high at 30.74 USD By Investing.com

https://in.investing.com/news/stock-market-news/adaptive-biotechnologies-stock-hits-52week-high-at-3074-usd-93CH-5691667
Adaptive Biotechnologies (ADPT) stock reached a 52-week high of $30.74, reflecting a 108.26% increase over the past year. While InvestingPro data shows strong returns, including a 103% six-month surge, analysis suggests the shares may be overvalued compared to their Fair Value estimate. The company also reported a 39% year-over-year revenue increase in Q3 to $83.9 million, surpassing Wall Street forecasts and achieving profitability earlier than expected.

Is Adaptive Biotechnologies (ADPT) Still Below Fair Value On Mixed Q3 Results?

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adpt/adaptive-biotechnologies/news/is-adaptive-biotechnologies-adpt-still-below-fair-value-on-m
Adaptive Biotechnologies (ADPT) recently reported mixed Q3 2026 earnings, with lower sales and profit compared to the previous year, yet demonstrating higher year-to-date revenue despite a deeper cumulative loss. The stock has seen significant short-term gains, with a 1-day return of 4.29% and a 7-day gain of 11.65%. Despite a current valuation indicating it is 7% undervalued at $27.98 against a fair value of $30.21, analysts caution that this assessment could change if clonoSEQ pricing faces pressure or if the Immune Medicine unit fails to secure new deals.

Adaptive Biotechnologies president and COO Julie Rubinstein sells $954k stock

https://www.investing.com/news/insider-trading-news/adaptive-biotechnologies-president-and-coo-julie-rubinstein-sells-954k-stock-93CH-5009476
Julie Rubinstein, President and COO of Adaptive Biotechnologies Corp (NASDAQ:ADPT), sold approximately $954,441 worth of common stock between November 4 and November 6, 2026, following the exercise of stock options. The transactions were executed under a Rule 10b5-1 trading plan. The company recently reported a 39% increase in third-quarter revenue, reaching $83.9 million, surpassing Wall Street forecasts and achieving profitability ahead of schedule.

Form 4 Adaptive Biotechnologies Corp: Julie Rubinstein (President and COO) For: 4 November

https://in.investing.com/news/stock-market-news/form-4-adaptive-biotechnologies-corp-julie-rubinstein-president-and-coo-for-4-november-93CH-5688386
This article reports on a Form 4 filing for Adaptive Biotechnologies Corp, detailing a transaction by Julie Rubinstein, the company's President and COO, on November 4th. The filing is a standard disclosure of insider trading activity. The article is brief, serving mainly as an alert about the regulatory filing.
Advertisement

Form 4 Adaptive Biotechnologies Corp: Julie Rubinstein (President and COO) For: 4 November

https://uk.investing.com/news/stock-market-news/form-4-adaptive-biotechnologies-corp-julie-rubinstein-president-and-coo-for-4-november-93CH-4966091
This article reports on a Form 4 filing for Adaptive Biotechnologies Corp, detailing an insider transaction involving Julie Rubinstein, the company's President and COO, on November 4th. The filing indicates her activity related to the company's stock, ADPT. The stock showed a gain of 4.29% at the time of publication.

The COO of Adaptive Biotechnologies (ADPT) exercises $12.14 options and sells 35,643 shares.

https://www.stocktitan.net/sec-filings/ADPT/form-4-adaptive-biotechnologies-corp-insider-trading-activity-92e2b3836e60.html
Adaptive Biotechnologies President and COO Julie Rubinstein exercised 35,643 stock options at $12.14 per share across November 4, 5, and 6, 2026, and subsequently sold the equivalent number of common shares at weighted-average prices ranging from $25.78 to $27.88. These transactions, conducted under a Rule 10b5-1 trading plan adopted in November 2025, resulted in an approximate pre-tax spread of $522K. After these transactions, Rubinstein holds 58,990 stock option contracts and 377,802 common shares directly.

Adaptive Biotechnologies earnings beat by $0.11, revenue topped estimates

https://www.investing.com/news/earnings/adaptive-biotechnologies-earnings-beat-by-011-revenue-topped-estimates-5001890
Adaptive Biotechnologies (NASDAQ: ADPT) reported strong third-quarter results, beating analyst estimates with an EPS of $0.020, significantly higher than the projected $-0.093. The company also surpassed revenue expectations, bringing in $83.9M against a consensus estimate of $71.57M. Following these positive results, Adaptive Biotechnologies' stock closed at $26.71, showing a 7.140% increase over the last three months and a 71.660% increase over the past year.

Quarterly Sales Slip Might Change The Case For Investing In Adaptive Biotechnologies (ADPT)

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adpt/adaptive-biotechnologies/news/quarterly-sales-slip-might-change-the-case-for-investing-in
Adaptive Biotechnologies (ADPT) reported a sales slip in Q3 2026 to US$83.9 million from US$93.97 million year-over-year, with net income falling to US$2.88 million. Despite higher nine-month sales, the company recorded a larger net loss, shifting investor focus to execution and cost discipline. Analysts project revenue of US$484.0 million and earnings of US$18.3 million by 2029, indicating a potential 13% upside.

Adaptive Biotechnologies Q3FY26 Results: Revenue rises 39% to $83.9 million

https://scanx.trade/stock-market-news/companies/adaptive-biotechnologies-q3fy26-results-revenue-rises-39-83-9-million/55383818
Adaptive Biotechnologies reported strong third-quarter 2026 financial results, with total revenue increasing by 39% year-over-year to $83.9 million, primarily driven by a 44% growth in core Minimal Residual Disease (MRD) revenue. The company achieved profitability ahead of schedule, posting an adjusted EBITDA of $14.3 million and a GAAP net income of $2.8 million. Management also raised its full-year 2026 MRD revenue guidance due to robust clinical testing volumes and pharma sequencing performance.
Advertisement

Adaptive Biotechnologies (NASDAQ:ADPT) Announces Earnings Results, Beats Expectations By $0.12 EPS

https://www.marketbeat.com/instant-alerts/earnings-adaptive-biotechnologies-nasdaq-adpt-announces-earnings-results-beats-expectations-by-012-eps-2026-11-04/
Adaptive Biotechnologies (NASDAQ:ADPT) reported its quarterly earnings, beating analyst expectations with an EPS of $0.02 against an estimated loss of $0.10. The company also surpassed revenue estimates, reporting $83.9 million compared to the consensus of $71.57 million, driven by strong measurable residual disease (MRD) revenue growth. Despite the positive earnings surprise, revenue was down 10.7% year-over-year, and the company does not expect full-year GAAP net income or positive EPS, with risks remaining due to Medicare testing frequency and uncertain expanded coverage.

Adaptive Biotechnologies Q3 2026 Earnings Call Transcript

https://www.benzinga.com/news/26/11/62898958/adaptive-biotechnologies-q3-2026-earnings-call-transcript
Adaptive Biotechnologies (NASDAQ: ADPT) reported strong Q3 2026 financial results, achieving profitability ahead of expectations with a 44% year-over-year increase in MRD revenue. The company raised its full-year 2026 MRD revenue guidance, driven by robust clinical testing volumes and pharma sequencing. Strategic advancements include expanded commercial and Medicaid coverage for clonoSEQ, active engagement with MolDX for a multiple myeloma maintenance testing bundle, and significant growth in its MRD pharma business backlog.

clonoSEQ tests rose 46% at Adaptive Biotechnologies (ADPT), yet total revenue fell.

https://www.stocktitan.net/sec-filings/ADPT/8-k-adaptive-biotechnologies-corp-reports-material-event-72ff68aba43e.html
Adaptive Biotechnologies (ADPT) reported a 11% year-over-year revenue decrease in Q3 2026, totaling $83.9 million, despite a 46% increase in clonoSEQ tests delivered. Minimal Residual Disease (MRD) revenue, excluding a Genentech agreement, saw a 39% rise, and the company achieved total profitability ahead of expectations with adjusted EBITDA of $14.3 million. Adaptive also raised its full-year MRD revenue guidance to $276-$286 million.

Adaptive Biotechnologies: Q3 Earnings Snapshot

https://www.10tv.com/article/syndication/associatedpress/adaptive-biotechnologies-q3-earnings-snapshot/616-599257dd-4eaf-46a8-9c11-7dcc54a2dbd1
Adaptive Biotechnologies Corp. (ADPT) reported a third-quarter profit of $2.9 million, or 2 cents per share, significantly exceeding Wall Street's expectation of a 10-cent loss per share. The company's revenue reached $83.9 million, also surpassing analyst forecasts. Shares of Adaptive Biotechnologies have seen a 64% increase year-to-date and a 58% rise over the past 12 months.

Adaptive Biotechnologies Reports Third Quarter 2026 Financial Results

https://www.globenewswire.com/news-release/2026/11/04/3395832/0/en/adaptive-biotechnologies-reports-third-quarter-2026-financial-results.html
Adaptive Biotechnologies (Nasdaq: ADPT) announced strong financial results for the third quarter of 2026, achieving total company profitability ahead of schedule with $14.3 million in adjusted EBITDA and $7.7 million in free cash flow. The company reported $83.9 million in revenue, driven by a 44% growth in core MRD revenue, and raised its full-year 2026 MRD revenue guidance to a range of $276 million to $286 million. These positive results are supported by new clinical guidelines and a definition of cure for multiple myeloma that emphasize the importance of MRD testing.
Advertisement

Form 4 Adaptive Biotechnologies Corp: Julie Rubinstein (President and COO) For: 30 October

https://ca.investing.com/news/stock-market-news/form-4-adaptive-biotechnologies-corp-julie-rubinstein-president-and-coo-for-30-october-93CH-4927511
This article reports on a Form 4 filing for Adaptive Biotechnologies Corp, detailing transactions made by Julie Rubinstein, the company's President and COO, on October 30. Form 4 filings are mandatory reports disclosing changes in beneficial ownership of securities by a company's officers, directors, and any beneficial owner of more than 10% of a class of the company's equity securities. The filing provides transparency into insider trading activities.

Adaptive Biotechnologies president and COO Julie Rubinstein sells $928,891 in stock

https://www.investing.com/news/insider-trading-news/adaptive-biotechnologies-president-and-coo-julie-rubinstein-sells-928891-in-stock-93CH-4997073
Adaptive Biotechnologies President and COO Julie Rubinstein sold $928,891 worth of company stock through a series of transactions from October 30 to November 3, 2026. These sales followed the exercise of stock options and were executed under a Rule 10b5-1 trading plan, after the stock saw a 78% surge over six months. The company also recently received "buy" ratings and increased price targets from Goldman Sachs and BTIG, indicating growing investor confidence.

Under a trading plan, Adaptive Biotechnologies (ADPT) COO sells 35,643 shares.

https://www.stocktitan.net/sec-filings/ADPT/form-4-adaptive-biotechnologies-corp-insider-trading-activity-575ba1e80f64.html
Adaptive Biotechnologies' President and COO, Julie Rubinstein, sold a total of 35,643 common shares across October 30, November 2, and November 3, 2026. These sales were executed under a Rule 10b5-1 trading plan adopted on November 18, 2025, following the exercise of fully vested stock options at $12.14 per share. The transactions generated approximately $929K in gross sale proceeds, with an estimated pre-tax spread of $496K.

BTIG Maintains Adaptive Biotechnologies(ADPT.US) With Buy Rating, Maintains Target Price $34

https://www.moomoo.com/news/post/1000023575/btig-maintains-adaptive-biotechnologies-adptus-with-buy-rating-maintains-target
BTIG has reiterated its Buy rating for Adaptive Biotechnologies (ADPT.US) and maintained its target price at $34. This indicates a continued positive outlook from the firm regarding the company's stock performance and future prospects.

Adaptive Biotechnologies president Julie Rubinstein sells $998k in shares

https://www.investing.com/news/insider-trading-news/adaptive-biotechnologies-president-julie-rubinstein-sells-998k-in-shares-93CH-4985633
Adaptive Biotechnologies President and COO Julie Rubinstein sold nearly $1 million in company shares between October 27-29, 2026, under a pre-established trading plan. The sales occurred as the stock neared its 52-week high, despite InvestingPro analysis suggesting it is overvalued. Concurrently, Rubinstein exercised stock options to acquire an equal number of shares.
Advertisement

Form 4 Adaptive Biotechnologies Corp: Julie Rubinstein (President and COO) For: 27 October

https://uk.investing.com/news/stock-market-news/form-4-adaptive-biotechnologies-corp-julie-rubinstein-president-and-coo-for-27-october-93CH-4943762
This article reports a Form 4 filing for Adaptive Biotechnologies Corp, detailing a transaction involving Julie Rubinstein, the company's President and COO, on October 27. The Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) whenever there is a change in the ownership of company stock by an insider. The specific details of the transaction are not provided in this brief announcement.

COO sells 35,643 shares at Adaptive Biotechnologies (ADPT), also exercising options at $12.14.

https://www.stocktitan.net/sec-filings/ADPT/form-4-adaptive-biotechnologies-corp-insider-trading-activity-0cd09f99546e.html
Adaptive Biotechnologies President and COO Julie Rubinstein sold a total of 35,643 shares across three days (October 27-29, 2026) at weighted average prices ranging from $26.58 to $28.90. Concurrently, she exercised 11,881 stock options each day at an exercise price of $12.14 per share. These transactions were executed under a Rule 10b5-1 trading plan adopted in November 2025.

Adaptive Biotechnologies Corporation (ADPT) Seasonal Returns Chart - Yahoo Finance

https://ca.finance.yahoo.com/quote/ADPT/seasonality/
The article provides a seasonal returns chart for Adaptive Biotechnologies Corporation (ADPT) on Yahoo Finance. It displays the average monthly price return for the stock from 2019 to 2026. The current stock price and after-hours trading information are also shown.

Form 4 Adaptive Biotechnologies Corp: Julie Rubinstein (President and COO) For: 22 October

https://ca.investing.com/news/stock-market-news/form-4-adaptive-biotechnologies-corp-julie-rubinstein-president-and-coo-for-22-october-93CH-4904260
This article reports on a Form 4 filing for Adaptive Biotechnologies Corp, detailing insider transactions by Julie Rubinstein, President and COO, for October 22. Form 4 filings provide transparency into company insider trading activities.

Adaptive Biotechnologies Must Show MRD Momentum Can Outrun Its Own Cautious Second-Half Guide

https://finviz.com/news/409181/adaptive-biotechnologies-must-show-mrd-momentum-can-outrun-its-own-cautious-second-half-guide
Adaptive Biotechnologies (ADPT) is approaching its third-quarter earnings report with strong momentum in its clonoSEQ minimal residual disease (MRD) franchise and a strategic separation of its MRD and Immune Medicine businesses. Despite this, headline numbers are expected to show contraction due to non-recurring items from the prior year, making it crucial for the underlying MRD business to exceed management's conservative second-half guidance. Investors will be looking for continued MRD volume and pricing strength, along with updates on the business separation and potential solid tumor expansion, to maintain the positive narrative.
Advertisement

Adaptive Biotechnologies Corp. (ADPT) Rallies on Earnings Beat, Raised Outlook, and Cash-Flow Targets

https://finance.yahoo.com/healthcare/articles/adaptive-biotechnologies-corp-adpt-rallies-145442301.html
Adaptive Biotechnologies Corp. (ADPT) saw its stock rally after reporting stronger-than-expected Q3 2026 results, raising its financial outlook, and reaffirming its target for profitability and positive free cash flow by year-end. The company's clonoSEQ product, used for detecting minimal residual disease in blood cancers, received a boost from leading clinical guidelines specifically referencing it for monitoring multiple myeloma. This positive development could lead to broader adoption among cancer specialists.

COO exercises options at $12.14 and sells 35,643 Adaptive Biotechnologies (ADPT) shares under a trading plan.

https://www.stocktitan.net/sec-filings/ADPT/form-4-adaptive-biotechnologies-corp-insider-trading-activity-c4fda49d3df1.html
Adaptive Biotechnologies (ADPT) President and COO Julie Rubinstein exercised options for 11,881 common shares at $12.14 per share on three separate dates in October 2026. Concurrently, she sold a total of 35,643 shares in six lots at weighted-average prices ranging from $24.38 to $26.30. These transactions were executed under a Rule 10b5-1 trading plan established on November 18, 2025.

Insider Selling: Adaptive Biotechnologies (NASDAQ:ADPT) COO Sells 11,881 Shares of Stock

https://www.marketbeat.com/instant-alerts/insider-insider-selling-adaptive-biotechnologies-nasdaq-adpt-coo-sells-11881-shares-of-stock-2026-10-26/
Adaptive Biotechnologies (NASDAQ:ADPT) COO Julie Rubinstein recently sold 11,881 shares of the company's stock at an average price of $24.98, totaling approximately $296,787. This sale was part of a pre-arranged Rule 10b5-1 trading plan and reduced her direct ownership by 3.05%. Analysts currently hold a "Moderate Buy" consensus for ADPT with an average price target of $30.06, despite the company reporting a wider-than-expected loss per share in its latest quarterly earnings.

Adaptive Biotechnologies (NASDAQ:ADPT) COO Sells 11,881 Shares of Stock

https://www.marketbeat.com/instant-alerts/insider-adaptive-biotechnologies-nasdaq-adpt-coo-sells-11881-shares-of-stock-2026-10-26/
Adaptive Biotechnologies COO Julie Rubinstein sold 11,881 shares of ADPT stock on October 26, 2026, for over $309,000, reducing her ownership by 3.05%. This transaction was part of a pre-arranged trading plan, and comes amidst a series of sales by Rubinstein in October. The stock saw a 3.0% increase to $26.27 following the news, and analysts maintain a "Moderate Buy" consensus.

Adaptive Biotechnologies president and COO Julie Rubinstein sells $897k shares

https://www.investing.com/news/insider-trading-news/adaptive-biotechnologies-president-and-coo-julie-rubinstein-sells-897k-shares-93CH-4973964
Julie Rubinstein, President and COO of Adaptive Biotechnologies Corp (NASDAQ:ADPT), sold shares worth $897,456 and acquired shares through option exercises valued at $432,706 between October 22 and October 26, 2026. These transactions were executed under a Rule 10b5-1 trading plan. The stock has seen an 86% surge over the past six months, and the company is scheduled to report earnings on November 4, 2026.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement